Next Article in Journal
The Dual Role of Inflammation in Colon Carcinogenesis
Next Article in Special Issue
Effects of Intramolecular Distance between Amyloidogenic Domains on Amyloid Aggregation
Previous Article in Journal
Tissue Microarray-Based Evaluation of Chromatin Assembly Factor-1 (CAF-1)/p60 as Tumour Prognostic Marker
Previous Article in Special Issue
Effects of Humidity and Surfaces on the Melt Crystallization of Ibuprofen
Int. J. Mol. Sci. 2012, 13(9), 11063-11070; doi:10.3390/ijms130911063
Case Report

Successful Treatment of Liver Aspergilloma by Caspofungin Acetate First-Line Therapy in a Non-Immunocompromised Patient

1,* , 2
, 1
, 1
 and 1
Received: 18 July 2012; in revised form: 20 August 2012 / Accepted: 29 August 2012 / Published: 6 September 2012
(This article belongs to the Special Issue Molecular Self-Assembly 2012)
View Full-Text   |   Download PDF [1292 KB, uploaded 19 June 2014]   |   Browse Figures
Abstract: Aspergillosis remains to be a life-threatening complication in immunocompromised patients. However, Aspergillus infection can be observed in non-immunocompromised individuals in rare cases. We report a case of liver aspergilloma in a chronic aplastic anemia patient under relatively intact immune status. Therapeutic strategy for this rare condition was extensively discussed and caspofungin acetate single agent first-line therapy was applied after careful consideration. Encouraging clinical and radiologic improvements were achieved in response to the antifungal salvage. Our long-term follow-up study also revealed a favorable prognosis. Based on this experience, we suggest caspofungin acetate as first-line therapy for treatment plans of liver aspergilloma.
Keywords: aspergillosis; liver; Aspergillus fumigatus; caspofungin acetate aspergillosis; liver; Aspergillus fumigatus; caspofungin acetate
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Bai, Q.-X.; Huan, Y.; Wang, J.-H.; Yang, L.-J.; Dong, H.-J. Successful Treatment of Liver Aspergilloma by Caspofungin Acetate First-Line Therapy in a Non-Immunocompromised Patient. Int. J. Mol. Sci. 2012, 13, 11063-11070.

AMA Style

Bai Q-X, Huan Y, Wang J-H, Yang L-J, Dong H-J. Successful Treatment of Liver Aspergilloma by Caspofungin Acetate First-Line Therapy in a Non-Immunocompromised Patient. International Journal of Molecular Sciences. 2012; 13(9):11063-11070.

Chicago/Turabian Style

Bai, Qing-Xian; Huan, Yi; Wang, Jian-Hong; Yang, Li-Jie; Dong, Hong-Juan. 2012. "Successful Treatment of Liver Aspergilloma by Caspofungin Acetate First-Line Therapy in a Non-Immunocompromised Patient." Int. J. Mol. Sci. 13, no. 9: 11063-11070.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert